Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Hospital Acquired Infection Control Market Size To Reach $8.1 Billion By 2028: Grand View Research, Inc.

Published

3 years ago

on

 

The global hospital acquired infection control market size is anticipated to reach USD 8.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 4.9% from 2021 to 2028. The key factors driving the market growth include the rising incidence of Hospital Acquired Infections (HAIs), supportive government initiatives, and the COVID-19 pandemic. The COVID-19 pandemic has emerged as a major catalyst for the market as it led to increased awareness and concern over HAIs. The demand for infection control equipment and consumables also stemmed from the need to stop the spread of COVID-19.

Key Insights & Findings:

  • The consumables segment dominated the market and accounted for the largest revenue share of 47.0% in 2020. This was owing to the high usage of consumables in hospitals and ambulatory care centers. The COVID-19 pandemic further contributed to the segment share due to the increased need for disposable, safe, and effective solutions to curb the spread of the virus. These included products such as N95 masks, PPE, and gloves.
  • The hospitals and Intensive Care Units (ICUs) segment held the largest revenue share of 46.0% in 2020 due to the high prevalence of healthcare-associated infections (HCAIs) in these facilities. According to CDC estimates, about 1 out of 31 hospital patients suffer from at least one HAI on any given day.
  • In Asia Pacific, the market is anticipated to witness lucrative growth in coming years owing to increasing supportive government initiatives to promote HAIs control products in the region.
  • Strategic initiatives by market players are mergers and acquisitions, collaboration, geographic expansions, and new product development. For example, in November 2020, Getinge acquired a manufacturer of decontamination products-Quadralene. The company was merged into Getinge’s Infection Control portfolio to expand its offerings in the business area of Surgical Workflows.

Read 120 page market research report, “Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report By Type (Equipment, Services, Consumables), By End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers), By Region, And Segment Forecasts, 2021 – 2028“, By Grand View Research.

Governments and regulatory bodies prescribed several policies and guidelines to prevent cross-contamination and safeguard public health. To prevent nosocomial infections in healthcare facilities, infection control standards were implemented such as triage strategy and provision and proper distribution of equipment, in addition to standard precautions such as hand washing and use of personal protective equipment. In particular, the pandemic resulted in a surge in demand for consumables such as PPE, masks, and disinfectants.

The CDC, of the U.S. Department of Health and Human Services, provides an extensive library of guidelines on basic infection prevention and control, antibiotic resistance, device-associated infections, procedure-associated infections, and disease / organism-specific to promote the control of HAIs. In the wake of the pandemic, the CDC added COVID-19 infection control guidelines to its digital library.

Growing initiatives by market players also contribute to the growth of the market. These initiatives include strategic partnerships, mergers and acquisitions, and product development. In February 2021, for instance, Getinge expanded its partnership with XPO Logistics under which the latter will provide warehousing and transport services from the Netherlands to the EMEA region for the company’s infection control business unit. In December 2020, Xenex launched LightStrike 6 as part of its patented lineup of pathogen-eliminating robots. The robots produce high-intensity broad-spectrum UV light and can also deactivate the COVID-19 virus in 2 minutes.

Grand View Research has segmented the global hospital acquired infection control market on the basis of type, end user, and region:

  • Hospital Acquired Infection Control Type Outlook (Revenue, USD Million, 2016 – 2028
    • Equipment
      • Sterilization Equipment
        • Heat Sterilization Equipment
          • Moist Heat Sterilization
          • Dry Heat Sterilization
        • Low Temperature Sterilization
        • Radiation Sterilization
        • Others
      • Disinfection Equipment
        • Washer Disinfector
        • Flusher Disinfector
        • Endoscopic Reprocessor Systems
    • Services
    • Consumables
      • Disinfectants
      • Sterilization Consumables
      • Others (Waste Disposal, PPE)
  • Hospital Acquired Infection Control End-user Outlook (Revenue, USD Million, 2016 – 2028)
    • Hospitals and Intensive Care Units (ICUs)
    • Ambulatory Surgical and Diagnostic Centers
    • Others (Nursing Homes and Maternity Centers)
  • Hospital Acquired Infection Control Regional Outlook (Revenue, USD Million, 2016 – 2028)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Latin America
      • Brazil
      • Mexico
      • Argentina
    • MEA
      • South Africa
      • Saudi Arabia
      • UAE

List of Key Players of Hospital Acquired Infection Control Market

  • Olympus Corporation
  • BD
  • Getinge AB
  • Xenex Disinfection Services Inc.
  • 3M
  • STERIS
  • ASP (Advanced Sterilization Products)
  • Ecolab
  • Belimed AG
  • KCWW (Kimberly-Clark Worldwide, Inc.)

Browse through more studies on the Global Medical Devices Industry, by Grand View Research.

  • Infection Control Market – Global infection control market size was estimated at USD 150.4 billion in 2016 and is anticipated to grow at a CAGR of 6.2% throughout the forecast period.
  • High Level Disinfection Services Market – Global high level disinfection services market size was valued at USD 22.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 9.2% from 2021 to 2028.
  • Sterilization Equipment Market – Global sterilization equipment market size was valued at USD 5.52 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 10.3% from 2021 to 2028.
Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024

Published

3 weeks ago

on

April 5, 2024

By

invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024

STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826

The following files are available for download:

https://mb.cision.com/Main/87/3956826/2712771.pdf

Invitation to presentation of EQT AB’s Q1 Announcement 2024

https://news.cision.com/eqt/i/eqt-ab-group,c3285895

EQT AB Group

 

View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs

Published

3 weeks ago

on

April 5, 2024

By

kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs
  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Published

3 weeks ago

on

April 5, 2024

By

biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update

VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html

Continue Reading

Trending